Last checked at 3 Oct 2016 11:28
3 October 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Issue of equity in respect of the exercise of options
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the issue and allotment of 3,441,000 new ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") pursuant to the exercise of 3,441,000 share options by certain employees. Of this number of share options, an amount of the share options have been exercised by persons discharging management responsibility ("PDMRs").
At the same time, the Company has received notice from certain PDMRs that they have immediately sold Ordinary Shares in respect of the share options exercised.
The exercise of share options and the sale of Ordinary Shares by the respective PDMRs are detailed below:
PDMR | Ordinary Shares received upon exercise of share options | Ordinary Shares sold | Price per Ordinary share sold | Resulting beneficial holding of Ordinary Shares | Resulting percentage of voting rights in the Company at Admission |
Sue Baker | 160,000 | 160,000 | 19.0p | 27,900 | 0.01% |
Alastair Friend | 80,000 | 80,000 | 19.5p | - | - |
Nunzio Di Grazia | 452,500 | 452,500 | 19.5p | - | - |
Bev Lees | 160,000 | 160,000 | 19.5p | - | - |
Russell Pickett | 160,000 | 160,000 | 19.5p | - | - |
Santiago Puig | 452,500 | 452,500 | 19.5p | - | - |
Murray Skinner | 160,000 | 160,000 | 19.5p | - | - |
Bodo Steinert | 452,500 | 226,250 | 19.5p | 388,262 | 0.07% |
Application has been made to the London Stock Exchange for admission to trading of the 3,441,000 new Ordinary Shares on AIM ("Admission") in respect of the exercise of the share options. It is expected that Admission will take place and that dealings in the new Ordinary Shares on AIM will commence at 8:00 a.m. on 6 October 2016, at which time the sale of Ordinary Shares will occur. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new Ordinary Shares.
Allergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 593,364,020 Ordinary Shares with voting rights attached. The Company has no Ordinary Shares in Treasury; therefore, the total number of voting rights in Allergy Therapeutics is 593,364,020. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.